Bend-capable tubular prosthesis

Abstract
A tubular prosthesis having a succession of turns around a longitudinal axis includes connectors between adjacent turns distributed around the circumference of the prosthesis. Each turn includes struts interspersed by inflection zones located at the axial ends of each turn such that, when the prosthesis expands radially, gaps open up between adjacent struts of each of the turn. The inflection zones are distributed regularly around the circumference so that the gaps are substantially the same size as each other around the circumference of the turn. The prosthesis may include a turn that exhibits a stagger zone within which the gap between adjacent struts is of an individual size different from that common to the other gaps of that turn. The inflection zones in that turn that lie circumferentially next to the stagger zone are displaced out of facing relationship with corresponding zones of inflection in the adjacent turn.
Description
TECHNICAL FIELD

This invention relates to tubular medical prostheses that are expandable from a radially compact disposition to a radially expanded disposition. In the compact disposition, the prosthesis can by delivered to its operational site in the body, typically trans-luminally and percutaneously, using a delivery system which is a sort of catheter. Exemplary of this class of prosthesis is a nickel titanium shape memory alloy stent for a bodily lumen which is often but not always an arterial lumen. See for example the disclosure of applicant's earlier WO 01/32102.


BACKGROUND

Bodily soft tissue is remarkably flexible and needs generally to be flexible. It is difficult for a metal stent to match bodily tissue for flexibility. WO 01/32102 is concerned with flexibility of the stent during its journey, from outside the body to the operational site within the body, as for example the catheter delivery system advances along a tortuous path from the point of entry in the body. However, there is also a need for metal stents (and other prostheses) that are destined to be installed at a location in the body where severe bending is to be expected. If the prosthesis could be made more tolerant of severe bending after placement, that would be attractive to doctors and their patients.


WO 01/32102 shows what could be termed a “classic” self-expanding stent structure of zig-zag stenting rings composed of struts interspersed by points of inflection and with adjacent stenting rings linked axially by connector portions. In the compact delivery disposition of the stent (FIG. 3 of WO 01/32102) the struts of the zig-zag rings are more or less parallel to each other so that each point of inflection represents a change of direction for the material of the stenting ring of more or less 180°. As the stent expands to its deployed configuration (FIG. 4 of WO 01/32102) the radius of the stenting ring expands by movement of the struts away from each other so that gaps open up between adjacent struts, and the adjacent points of inflection move further apart (but nevertheless remain spaced at equal intervals to each other around the circumference of the stenting ring).


The connectors serve to restrain relative circumferential movement of the zig-zag rings relative to each other. Thus, if the points of inflection of adjacent stenting rings are facing each other in the compact delivery disposition of the stent, as in WO 01/32102, then so will be these points of inflection still facing each other in the expanded disposition of the stent. When an expanded stent is subject, in the body, to extreme bending, so that the longitudinal axis of the stent is no longer a straight line but a pronounced curve (as in a banana), then the facing points of inflection on the inside of the bend approach each other. The more extreme the bending, the closer the facing points of inflection become until, in the end, these facing “peaks” abut each other or rub past each other.


Any such abutment or rubbing is undesirable. One way to guard against it is to choose a stent design that can be classified as a “peak-to-valley” design rather than a “peak-to-peak” design as seen in applicant's WO 01/32102. The art is replete with suggestions for peak-to-valley designs in which the peaks of any one zig-zag stenting ring do not face corresponding peaks of the next adjacent stenting ring but, instead, are circumferentially offset to the peaks of the next adjacent stenting ring by half of the gap between two adjacent peaks of the same ring, in the expanded disposition of the stent. Then, under extreme bending, any particular peak on the inside of the bend can advance into the V-shaped space between two peaks of the next adjacent stenting ring, without any abutment or rubbing on any portion of the material of the next adjacent stenting ring.


The present invention is concerned with the above-explained problem. It seeks to improve the in situ bend capability of stents including those seen in WO 01/32102. However, the invention also seeks to achieve this performance enhancement without sacrificing other attractive qualities of stents such as disclosed in WO 01/32102. For example, simplicity of modelling of stress distributions within the stent is attractive in the management of fatigue performance of metal stents. Manufacturing simplicity of course facilitates management of cost which should improve access to stents, for those people who need them.


Looking at WO 01/32102, one can quickly see that performance in extreme bending could be enhanced by extending the length of the portions that connect adjacent zig-zag stenting rings. The longer these “bridges” then the more the stent can bend without abutment of peaks on the inside of the bend. However, large axial gaps between adjacent stenting rings are not desirable, for then the tissue of the lumen that is being stented by the prosthesis is relatively unsupported, at least between adjacent stenting rings.


For the same reason, one seeks as far as possible to distribute the metallic material of the stent as evenly as possible over the length and circumference of the tubular envelope of the stent so that support for the stented tissue is as even and uninterrupted as possible. This of course indicates that all gaps between all adjacent struts and points of inflection of the stent matrix should be as constant as possible. Generally, one does not modulate the strut matrix of a stent, over the length and circumference of the stent, to suit tissue variations within the stenting site. Generally, one does not seek to place a particular point on the circumference of the stent in opposition to a particular zone of tissue within the stenting site. For these reasons alone, one seeks a stent matrix that is everywhere the same over the length and circumference of the prosthesis.


In principle, the problem addressed in the present invention, and the solution here disclosed, is useful in all classes of stenting prostheses. That is to say, it works with a stent matrix that exhibits the (spiral) turns around the axis of a helical stent, as well as with a stent that features a stack of endless stenting rings. It works with balloon-expandable stents and resilient self-expanding stents as well as with nickel titanium shape memory alloy stents.


SUMMARY

Nevertheless, according to the present invention, it is contemplated to depart from the prior good design practice, and deliberately configure the stent matrix so that it is locally different, at one point at least, around the circumference of at least every second stenting ring within the prosthesis. In short, we envisage within each stenting ring at least one location (we call it a “stagger zone”) where the gap between adjacent points of inflection is smaller (but it could be greater) than the otherwise constant (or near constant) “wavelength” around the circumference of the prosthesis for that particular stenting ring.


It will be appreciated that, for any particular pair of adjacent stenting rings, even just one such abnormal gap (stagger zone) could be enough to set up a circumferential offset between the otherwise facing “peak-to-peak” points of inflection that we see in, for example, FIG. 4 of WO 01/32102. In practice, however, a design with only one stagger zone on the circumference might not be enough to deliver the desired circumferential offset all around the circumference, especially in designs that feature a large number of struts, in any one turn around the axis of the prosthesis. Four stagger zones are likely to be enough. Designs with two, three or four such zones are presently preferred, but up to 6 stagger zones per turn are readily conceivable, the more so with stent design with a notably small mesh size in their matrix.


As mentioned above, it is the connectors between adjacent stenting rings that prevent adjacent stenting rings from rotating around the long axis of the prosthesis relative to each other and thereby preserve the designed intended relationship between facing stenting rings and their respective points of inflection. Generally, it will be convenient to incorporate the design variation that creates the abnormal gap between adjacent points of inflection with the design of the connector zone between two adjacent turns. Thus, in perhaps the simplest case, we can envisage a connector from which two struts extend into a stenting ring or turn on one side of the connector, and two other struts extend in the other axial direction, into the next adjacent stenting ring or turn. If the angle between the first two struts is “normal” for that stenting ring, but the angle between the opposite pair of struts, in the other of the two stenting rings, is much smaller than “normal”, then the points of inflection circumferentially on either side of the connector, that would be facing each other in the classic construction of WO 01/32102, will be circumferentially offset from each other, because of the different angle of the struts each side of the connector. Think of the connector as the trunk of a human body, with the legs of the body slightly open and the two arms of the body. Imagine the angle between the upwardly outstretched arms significantly greater than the angle between the legs.


Rather than set out a string of statements of invention, and then repeat them in a set of claims, we opt for economy of text, refrain from reciting statements of invention, and present various aspects of the above explained inventive concept in claims appended to this description.


We have stated that setting up a “peak-to-valley” configuration of otherwise facing inflection zones is conveniently incorporated in the design of portions that connect adjacent stenting rings (or helical turns). However, one can readily envisage that the necessary offset can be created in a stagger zone that is circumferentially spaced from connectors. There is no imperative that the stagger zone must be coincident with the connector zone.


It will be evident that a stagger zone can be created in a number of different ways. One can locally manipulate the mechanical properties of the material of the stagger zone, not just be local modulation of the dimensions of the inflection points or struts within the stagger zone, relative to the rest of the circumference of the stenting ring, but could also contemplate manipulation of the mechanical properties of the material in the stagger zone by local heat treatment or even chemical treatment. It is even possible to envisage adding components to an otherwise “classic” stenting ring structure as in WO 01/32102, such as a flexible “tie” between the two struts that are destined to deliver a smaller than usual gap between adjacent points of inflection. When a painter erects an easel, there is a “piece of string” that runs between the front frame of the easel, and the rear strut of the easel, not far above the ground, where the gap between the front legs of the easel and the single rear leg of the easel rest on the ground. A classic stent such as shown in WO 01/32102 could be modified by inclusion in it of judiciously placed “pieces of string” from biologically compatible material, in order to restrain two adjacent struts of selected stenting rings of the prosthesis from opening to the full extent that occurs for all the other struts of that particular stenting ring. (We mention this possibility not with any expectation that it will be a preferred construction, but in the recognition that competitors stimulated by the present disclosure might be obliged to turn to such constructions in the hope of avoiding the inventive concept of the present application). The motto “keep it simple” is rather powerful and the present inventors are proud of a contribution to the art that is essentially simple but should deliver a powerful enhancement of performance.


At this juncture, it is worth noting that a shape memory alloy stent is given its “remembered” configuration by a heat treatment. In the case of WO 01/32102, that heat treatment is given with the points of inflection arranged “peak-to-peak”. With shape memory alloy stents embodying the present invention, however, the heat treatment is with the inflection points arranged as intended, therefore, not peak to peak, but in the circumferentially staggered arrangement brought about by the stagger zone(s).


In the context of the present invention, attention is directed to the disclosure of US/2004/0073290 and, in particular, drawings FIGS. 4 and 5 and the associated text. We see adjacent zig-zag stenting rings with points of inflection that are more or less “peak-to-peak” in the compact configuration of drawing FIG. 4, but not so much peak-to-peak in the expanded configuration of drawing FIG. 5. However, the struts of any particular zig-zag stenting ring are not all the same length. Some are relatively long, some are relatively short, and some are of intermediate length. By contrast, it appears that the angle that opens up between any two struts that diverge from any particular point of inflection is always the same, so that any technical effect of circumferential displacement of peak-to-peak points of inflection is accomplished not by local variation of an angle between two adjacent struts but, rather, by modulations of the length of adjacent struts in each of the stenting rings. Putting it another way, each connector portion 24 is the intersection of two straight lines in the form of an “X” shape and this is not what is envisaged with the present invention.


Thinking about the bend capability of any particular stent design, this might be limited by peak to peak abutment on the inside of the (banana) bend but could also be restricted by incipient buckling of the stent matrix at some point on the matrix. Clearly, to obtain benefit from the present invention, the stent matrix to which it is to be applied must be capable of bending without buckling, to the extent needed to bring the benefits of the present invention into play. In general, the sparser the population of connectors, the more capacity the lattice will have to bend without buckling.





BRIEF DESCRIPTION OF THE DRAWINGS

For a better understanding of the present invention, and to show more clearly how the same may be carried into effect, reference will now be made, by way of example, to the accompanying drawings, in which:



FIGS. 1 and 2 show, respectively content of FIGS. 6 and 2 of US/2003/0055485, being a tubular stent structure opened out flat, seen in plan view, in respectively the radially compact and radially expanded dispositions;



FIG. 3 is a reproduction of FIG. 5 of US/2004/0073290, being a portion of a tubular stent structure, opened out flat, and in a radially expanded configuration;



FIGS. 4 and 5 reproduce drawing FIGS. 3 and 4 of applicant's WO 01/32102, being respectively side views of a stent structure in the radially compact and radially expanded dispositions;



FIGS. 6 and 7 are corresponding views of a stent structure in accordance with the present invention; and



FIGS. 8 and 9 are views corresponding to those of FIGS. 4 and 5, or FIGS. 6 and 7, showing another embodiment of the present invention.





DETAILED DESCRIPTION


FIGS. 1 to 5 give only the most cursory impression of the wealth of stent strut matrix proposals contained within the state of the art. However, they provide enough disclosure to set the advantages of the present invention in the context of relevant prior art.


Looking first at FIGS. 1 and 2, we see an example of a stent 10 which utilises circumferential support structures 12 in the form of zig-zag stenting rings. These are spaced apart along the long axis of the stent. They are made up of struts 12 interspersed by points of inflection 18 which US/2003/0055485 designates “apex portions”. These apex portions are mostly free to take up positions, in the expanded FIG. 2 disposition of the stent, which are governed only by the stresses transmitted through the struts of that particular stenting ring, or transmitted to that stenting ring by the bodily tissue that presses against it. However, there are also connecting struts 16 each of which joins a selected one of the apex portions of one stenting ring with a selected apex portion of an adjacent stenting ring. From FIG. 1, we see that the connecting struts have length direction that is in the circumferential direction of the stent tube, so that the opposite ends of each particular connecting strut 16 are circumferentially spaced from each other. In the radially compact disposition of FIG. 1, the circumferentially extending connecting strut 16 spans an intervening apex portion between its two ends. However, when the stent expands into its radially expanded configuration represented by FIG. 2, the circumferential length of the connecting strut 16 is not enough to span across an intervening apex portion, because the apex portions arranged around the circumference of any particular stenting ring have moved away from each other by an amount greater than the length of the connecting strut. By selecting a connecting strut length that is approximately half the distance between two adjacent apex portions of the same stenting ring, in the expanded configuration of the stent, one can achieve a “staggering” of the evenly spaced apex portions of one stenting ring, relative to the equal spacing of the apex portions of the next adjacent stenting ring that “faces” the stenting ring of the other end of the connecting strut.


In consequence, when the stent in its expanded configuration is subject to longitudinal compression, or when it is bent sharply (so that its longitudinal axis is not longer straight but arcuate) the facing apex portions on the inside of the bend, or that approach each other as the stent is longitudinally compressed do not butt up against each other but, instead, move into the free gap between two spaced apart apex portions of the other of the two facing stenting rings.


In US/2003/0055485, paragraph 0031, it is stated that the geometry of the stent in the radially compact delivery disposition of FIG. 1 is “highly flexible” so that it can tolerate axial compression on the inside of a bend as described above. Looking at FIG. 1 (FIG. 6 of the US publication) it is not immediately evident how the stated flexibility is provided.


We turn now to FIG. 3, which corresponds to FIG. 5 of US/2004/0073290. In this case, one can see that the connector portions between adjacent zig-zag stenting rings have a very simple construction. They are remarkably short in length but, to the extent that they have a length direction, it is parallel to the longitudinal axis of the stent, rather than in a circumferential direction. Accordingly, there is no circumferential offset between the apex portions facing each other and connected by the connector strut 24.


Nevertheless, we see from FIG. 3, that there is a circumferential offset between unconnected apex portions of adjacent stenting rings.


The offset is accomplished by providing a range of different strut lengths in any particular stenting ring. In particular, each connector 24 is at the apex of a first pair of relatively long struts and a second pair of relatively short struts. Each stenting ring features struts of three different lengths, namely A) short, B) intermediate length and C) long. And we see from FIG. 3 how the strut length progresses around the circumference of each stenting ring in a sequence ABCCBA. We can see how the apex portions at the open end of a bifurcation between two A-struts both fall within a single gap between two C-struts of the adjacent stenting ring. This overlap occurs periodically around the circumference of the prosthesis, on each occasion midway between two adjacent connector portions 24.


In the compact disposition of the stent of FIG. 3, apex portions are “head-to-head” or “peak-to-peak” all the way around the circumference of the stenting cylinder, not just at those locations where a connector portion 24 lies between the head-to-head apex portions. In this respect, there is reduced flexibility in the compact delivery disposition of the stent device, comparable with that of the device of FIG. 1 described above. Again, it is not immediately evident how the device delivers bent flexibility in the compact delivery disposition.


The present applicant specialises in self-expanding stent devices that are formed from a tubular workpiece of nickel titanium shape memory alloy (“NITINOL” trademark). The tube is formed into a stent precursor by forming in it a multiplicity of slits (cut by a laser) that it is convenient to provide all mutually parallel to each other and to the long axis of the tubular workpiece. One such construction can be seen in FIG. 4, this corresponding to FIG. 3 of applicant's earlier publication WO 01/32102, the contents of which are hereby incorporated by reference. Reference to the WO document will reveal how, following laser cutting, portions of the tubular workpiece are removed to leave “holes” in the slitted tube, indicated by reference 60 in FIG. 4. It will be grasped by the skilled reader that provision of these voids in the slitted tube endows the tube, in its delivery system, confined by a sheath that prevents premature self-expansion, greater flexibility for the sheath to advance along a tortuous delivery path to a site of stenting in the body.



FIG. 5 shows the expanded disposition of the FIG. 4 stent construction. A pattern of zig-zag stenting rings connected by short connecting portions 62 can be readily recognised and it can also be seen that the apex portions (here in designated “points of inflection”) of adjacent zig-zag stenting rings are facing each other, not only across the connected 62 but also elsewhere around the circumference of the stenting device. Thus, when the expanded stenting device of FIG. 5 is subject to severe lengthwise compressive stress, or severe bending, there is a possibility for facing points of inflection of axially adjacent zig-zag stenting rings to approach each other closely, or even touch on the inside of the bend. The problem being tackled when the present invention was made was how to reduce the likelihood of this adverse event occurring.


One embodiment of the present invention, which does succeed in setting the facing points of inflection of adjacent stenting rings circumferentially offset from each other, will now be described be reference to drawings FIGS. 6 and 7.



FIG. 6 shows a distribution of slits in a tubular workpiece opened out flat, and the similarity with the slit distribution of FIG. 4 is immediately apparent. Note that FIG. 4 is a view from the side of the workpiece, and does not show the workpiece opened out flat whereas FIG. 6 shows the entire circumference of the tubular workpiece, laid out flat on the page. We see from FIG. 6 that there are two connecting struts 80 connecting any two adjacent stenting rings 82. We see at the left-hand end of FIG. 6 the terminal stenting ring 84 which has a longer slit length and is also evident in FIG. 4. We note that FIG. 4 shows the entire length of the stent whereas FIG. 6 shows only a portion of the length of the stent. Whereas the connectors 80 are interspersed by voids 60 just as in FIG. 4, there are no voids between the increased length end stenting ring 84 and its next adjacent normal length stenting ring 82′. Whereas there are two connector portions 80 between the normal length stenting rings, there are 14 connectors 86 between the end stenting ring 84 and its neighbour 82′.


Noteworthy in FIG. 6 is the pattern of length of the individual slits cut by the laser. In general, the slits have a single length, but there are two exceptions. The first exception is that the slit length is longer at the end of the tubular workpiece, to form the end stenting ring 84. One such slit is marked in FIG. 6 with reference 88. The second exception is the length of the slit that terminates at one end of each connector portion 80. One such slit, of shorter length then the others, is designated in FIG. 6 with reference 90. We need to look at FIG. 7 to appreciate the consequence of short struts 90.



FIG. 7 reveals two of the many connector portions 80. Each connector 80 sits between two adjacent stenting rings at the points of inflection 92 of any one stenting ring are all to be found on a notional circular locus that is transverse to the longitudinal axis of the stent. A gap “t” exists between any particular such circular loci D and E facing each other at periodical intervals down the length of the stent. Within these two circles, we find a circumferential offset between the spaced apart points of inflection 92 in circle E and those of the facing circle D. The offset is found everywhere except at the periodically spaced connectors (in this example there are four) 80.


Turning our attention to the next adjacent pair of facing circles F and G in FIG. 7, the origin of the circumferential offset can be seen in the opposing relationship of the points of inflection 92A, B, C and D. The gap between apex 92B and 92C on the stenting ring that includes circle G is the regular gap between two struts of “normal” length. However, because of the reduced slit length 90, the circumferential gap between points of inflection 92A and 92D is abnormally small so that both points of inflection 92A and 92D “fit” in the normal sized gap between apex 92B and 92C of circle G. In the terminology adopted in the present specification, the zone that includes points of inflection 92A, B, C and D is designated a stagger zone. From FIG. 7 it is immediately evident that providing such a stagger zone by using an abnormally short slit length has a disadvantage, namely, that the gap between points of inflection 92A and 92D is shorter than the regular gaps between other points of inflection spaced around circle F. It hardly need be stated that optimal use of material within a stent matrix calls for a regular matrix of struts, with a minimal amount of material in the radially compact delivery disposition, and a uniformed distribution of that material in the expanded configuration (all gaps the same size) so as to achieve a maximum ratio of expanded diameter to radially compress delivery diameter. Deliberately accepting a plurality of unnecessarily small gaps around the circumference of each stenting ring will have an adverse effect on this ratio of diameters and is therefore not something of itself desirable to stent designers.


Nevertheless, the present invention is attractive, when taken in the context of balancing conflicting constraints on the stent designer. Looking at FIG. 6, one can see the evident simplicity of the stent strut and slit arrangement. The government regulatory authorities impose stringent quality requirements on stent manufacturers. For example, stents must meet stringent metal fatigue requirements. Finite element analysis of stent designs is of crucial importance. A design that is inherently simple should lend itself to reliable prediction of its properties in service. Being able to predict how a stent will perform after it has been installed in a human body is a significant advantage for stent manufacturers that compete to provide the stents most attractive to doctors and medical services.


Reference is now made to FIGS. 8 and 9. These have been annotated with references the same as are used in FIGS. 6 and 7, to identify corresponding features. Noteworthy is that there are four connectors rather than two, connecting adjacent stenting rings. Clearly, each stent ring comprises pairs of struts which are unconnected to any pairs of struts of an adjacent stent ring. Further is clear that a number of adjacent stent rings are spaced from each other. FIG. 8 shows the left-hand end of the stent whereas FIG. 9 shows the full length. Actually, the FIG. 9 stent is not the same as the FIG. 8 stent because FIG. 8 shows longer struts in the two end rings but FIG. 9 does not.


In FIG. 9, it is helpful to consider connectors 80A and 80B. The former has the asymmetric shape of all the other connectors of zig-zag rings 82. The latter has an X shape because it is part of the transition from the stagger zone rings 82 to the end ring 84 that lacks any stagger zone. Shown is that the closest end points of a pair of struts of one stent ring and a pair of struts of another stent ring are connected.


The embodiments illustrated in FIGS. 6 to 9 represent only one of a multitude of ways to bring about an angle between struts that is different from the otherwise regular angle between struts around the remainder of the circumference of any particular stenting ring. For example, one could locally modify the material of the stenting ring, either in the points of inflection at one or both ends of the struts that are to form the abnormal size gap, or by judicious modification of the dimensions of those points of inflection or the two struts running between them. Above-mentioned WO 01/32102 contemplates manual removal of individual scrap portions to create voids 60. There are voids 60 in FIG. 6. If manual intervention is to be relied upon to create the voids 60 in an embodiment of the present invention, then it would not be beyond the bounds of imagination to intervene locally, and manually, at portions of the abluminal surface of the workpiece where the properties of the material are to be modified locally in order to deliver a gap of different size, or angle of different size, between two adjacent struts of any particular stenting ring. One envisages that the material could be modified in its composition, by local application of a substance to cause a chemical reaction, or by local application of a substance to modify the microstructure of the material at that point, or by local application of heat or cooling to give the material at that location a different thermal history of that of the material of the remainder of the stenting ring.


In this context, we incorporate, by reference to it, the disclosure of WO2001/076508, from the present applicant, which explains how particular strut configurations can be created by using a jig to hold the workpiece in a particular desired configuration during the heat treatment which “sets” the “remembered” configuration of the struts in the shape memory alloy. Thinking along these lines, one could use instead of struts of different lengths a jig that holds the struts in a configuration such as is shown in FIG. 7, when giving the workpiece its “remembered” configuration, so that it should open up at the stenting site to the remembered disposition even if the length of slit 90 is just the same as the length of all the other slits in the stenting ring.


When thinking of workpieces of every day household dimensions, such as how to prevent a door opening too far, one would use a strut between the door and the frame that has a set length corresponding to the maximum opening that one wishes to impose on the door. In the same way, one could envisage some sort of collapsing tie to impose a maximum size on the gap between points of inflection 92A and 92D, that extends between the respective struts between the slit 90. Of course, stents are very small, but by no means as small as the nanometer dimensions that are in the minds of designers of medical devices, so there seems no justification for dismissing such tie pieces as impracticable. The reality is that, as stent designs become ever more sophisticated, so the range of applications for stents becomes ever greater and, with that, the demand for stents to mimic ever more closely the flexible behaviour of the original bodily tissue, especially when called upon, from time to time, to bend tightly along its length. The challenge is to build a stent that is strong enough to perform the stenting function which is after all the reason for its surgical implantation in the body while, at the same time, rendering the prosthesis as soft and bendy as possible in all other aspects. The present invention makes a valuable contribution to this objective.


Stents need not be made of nickel titanium alloy. Another biologically compatible material familiar to stent designers is stainless steel. Great efforts are currently being made to use other materials such as biologically compatible polymers. All such stents can benefit from the present invention regardless how they are formed. The illustrated embodiments are not limiting.


Stents need not display the same strut matrix over their entire length. We envisage embodiments in which only part of the length of the prosthesis is given the high flexibility of the present invention. Thus, there may be some turns of the stent matrix that include stagger zones, to deliver flexibility, and other parts of the length of the stent (e.g. end zones, or a mid-length portion) where high flexibility is contra-indicated, and so no stagger zones need be provided in these parts of the stent matrix.

Claims
  • 1. A stent comprising: first and second annular frames in alignment with each other to define a longitudinal axis, each annular frame having undulations circumscribing the longitudinal axis, the undulations including a plurality of struts traversing in generally opposed directions to define a plurality of end points disposed generally circumferentially about the longitudinal axis for the respective annular frame, the end points of the first annular frame in facing axial alignment with corresponding end points of adjacent annular frames when the stent is in an unexpanded configuration;at least one connector member coupled to a first pair of struts defining one endpoint of the first annular frame and a second pair of struts defining a second endpoint of the second annular frame, the struts of the first annular frame outside of the first pair of struts having generally the same length and the struts of the second annular frame outside of the second pair of struts having generally the same length, the first pair of struts having surfaces exposed to each other to define a first included angle different from a second included angle defined by the exposed surfaces of the second pair of struts so that end points of the first annular frame are offset in a circumferential direction with respect to the corresponding facing end points of an adjacent annular frame in an expanded configuration of the stent;
  • 2. The stent according to claim 1, wherein a connector member is disposed between every five struts including the strut connected to the connector member.
  • 3. The stent according to claim 1, wherein the end points of the first annular frame outside of the first pair of struts are generally aligned on a plane orthogonal to the longitudinal axis in both the unexpanded and expanded configurations.
  • 4. The stent according to claim 1, wherein the length of the first annular frame struts are generally the same as the length of the second annular frame struts.
  • 5. The stent according to claim 1, wherein the first annular frame comprises at least two first pair of struts and the second annular frame comprises at least two second pair of struts, wherein a separate connector member connects each of the at least two first pair of struts to a corresponding one of the at least two of the second pair of struts.
Priority Claims (1)
Number Date Country Kind
PCT/EP07/04407 May 2006 WO international
PRIORITY

This application is a continuation of U.S. patent application Ser. No. 12/300,985, filed as a U.S. national stage application under 35 USC §371 of International Application No. PCT/EP2007/004407, filed May 16, 2007, now U.S. Pat. No. 8,403,978, which claims priority to United Kingdom Patent Application No. 0609841.2, filed May 17, 2006, each of which is incorporated by reference in its entirety into this application.

US Referenced Citations (129)
Number Name Date Kind
5091205 Fan Feb 1992 A
5464419 Glastra Nov 1995 A
5527353 Schmitt Jun 1996 A
5591223 Lock et al. Jan 1997 A
5645532 Horgan Jul 1997 A
5725572 Lam et al. Mar 1998 A
5741327 Frantzen Apr 1998 A
5759192 Saunders Jun 1998 A
5800511 Mayer Sep 1998 A
5824042 Lombardi et al. Oct 1998 A
5824059 Wijay Oct 1998 A
5824077 Mayer Oct 1998 A
5843118 Sepetka et al. Dec 1998 A
5858556 Eckert et al. Jan 1999 A
5861027 Trapp Jan 1999 A
5868783 Tower Feb 1999 A
5922020 Klein et al. Jul 1999 A
6022374 Imran Feb 2000 A
6053940 Wijay Apr 2000 A
6056187 Acciai et al. May 2000 A
6086611 Duffy et al. Jul 2000 A
6099561 Alt Aug 2000 A
6174329 Callol et al. Jan 2001 B1
6241762 Shanley Jun 2001 B1
6270524 Kim Aug 2001 B1
6293966 Frantzen Sep 2001 B1
6312456 Kranz et al. Nov 2001 B1
6334871 Dor et al. Jan 2002 B1
6355057 DeMarais et al. Mar 2002 B1
6379381 Hossainy et al. Apr 2002 B1
6387123 Jacobs et al. May 2002 B1
6409752 Boatman et al. Jun 2002 B1
6451047 McCrea et al. Sep 2002 B2
6471721 Dang Oct 2002 B1
6475233 Trozera Nov 2002 B2
6478816 Kveen et al. Nov 2002 B1
6540777 Stenzel et al. Apr 2003 B2
6547818 Rourke et al. Apr 2003 B1
6562065 Shanley May 2003 B1
6585757 Callol Jul 2003 B1
6605110 Harrison Aug 2003 B2
6629994 Gomez et al. Oct 2003 B2
6676700 Jacobs et al. Jan 2004 B1
6770089 Hong et al. Aug 2004 B1
6797217 McCrea et al. Sep 2004 B2
6827734 Fariabi Dec 2004 B2
6878162 Bales et al. Apr 2005 B2
6979346 Hossainy et al. Dec 2005 B1
7060093 Dang et al. Jun 2006 B2
7135038 Limon Nov 2006 B1
7175654 Bonsignore et al. Feb 2007 B2
7381217 Tischler Jun 2008 B2
7462190 Lombardi Dec 2008 B2
7468071 Edwin et al. Dec 2008 B2
7479157 Weber et al. Jan 2009 B2
7691461 Prabhu Apr 2010 B1
7771463 Ton et al. Aug 2010 B2
7772659 Rodmacq et al. Aug 2010 B2
8043364 Lombardi et al. Oct 2011 B2
8152842 Schlun Apr 2012 B2
8292950 Dorn et al. Oct 2012 B2
8322593 Wack Dec 2012 B2
8403978 Schlun et al. Mar 2013 B2
8475520 Wack et al. Jul 2013 B2
8500793 Zipse et al. Aug 2013 B2
8518101 Dreher Aug 2013 B2
8551156 Wack et al. Oct 2013 B2
20020007212 Brown et al. Jan 2002 A1
20020116044 Cottone et al. Aug 2002 A1
20020116051 Cragg Aug 2002 A1
20020138136 Chandresekaran et al. Sep 2002 A1
20020193867 Gladdish et al. Dec 2002 A1
20020193869 Dang Dec 2002 A1
20020198589 Leong Dec 2002 A1
20030055485 Lee et al. Mar 2003 A1
20030135254 Curcio et al. Jul 2003 A1
20030144725 Lombardi Jul 2003 A1
20030216807 Jones et al. Nov 2003 A1
20030225448 Gerberding Dec 2003 A1
20040015228 Lombardi et al. Jan 2004 A1
20040015229 Fulkerson et al. Jan 2004 A1
20040034402 Bales et al. Feb 2004 A1
20040044401 Bales et al. Mar 2004 A1
20040073290 Chouinard Apr 2004 A1
20040073291 Brown et al. Apr 2004 A1
20040088043 Klein May 2004 A1
20040117002 Girton et al. Jun 2004 A1
20040230293 Yip et al. Nov 2004 A1
20040236400 Edwin et al. Nov 2004 A1
20040236409 Pelton et al. Nov 2004 A1
20040254637 Yang et al. Dec 2004 A1
20050049682 Leanna et al. Mar 2005 A1
20050060025 Mackiewicz et al. Mar 2005 A1
20050149168 Gregorich Jul 2005 A1
20050172471 Vietmeier Aug 2005 A1
20050182477 White Aug 2005 A1
20050184277 Su et al. Aug 2005 A1
20050222667 Hunt Oct 2005 A1
20050278019 Gregorich Dec 2005 A1
20060030934 Hogendijk et al. Feb 2006 A1
20060064153 Langhans et al. Mar 2006 A1
20060216431 Kerrigan Sep 2006 A1
20060241741 Lootz Oct 2006 A1
20060253187 Moriuchi et al. Nov 2006 A1
20060265049 Gray et al. Nov 2006 A1
20070112421 O'Brien May 2007 A1
20070219624 Brown et al. Sep 2007 A1
20080051885 Llanos et al. Feb 2008 A1
20080188924 Prabhu Aug 2008 A1
20090125092 McCrea et al. May 2009 A1
20090125099 Weber et al. May 2009 A1
20090200360 Wack Aug 2009 A1
20090204201 Wack Aug 2009 A1
20090204203 Allen et al. Aug 2009 A1
20090264982 Krause et al. Oct 2009 A1
20100016949 Wack Jan 2010 A1
20100070021 Wack et al. Mar 2010 A1
20100114298 Dorn et al. May 2010 A1
20100191321 Schlun et al. Jul 2010 A1
20100204784 Molaei et al. Aug 2010 A1
20100211161 Dreher Aug 2010 A1
20100234936 Schlun Sep 2010 A1
20100249903 Wack et al. Sep 2010 A1
20100298921 Schlun et al. Nov 2010 A1
20110196473 McCrea et al. Aug 2011 A1
20110198327 Prabhu Aug 2011 A1
20110245905 Weber et al. Oct 2011 A1
20110319977 Pandelidis et al. Dec 2011 A1
20120041542 Lombardi et al. Feb 2012 A1
Foreign Referenced Citations (81)
Number Date Country
04130431 Mar 1993 DE
29621207 Jan 1997 DE
19728337 Jan 1999 DE
29904817 May 1999 DE
10201151 Jul 2003 DE
202004014789 Jan 2005 DE
102004045994 Mar 2006 DE
0481365 Apr 1992 EP
0709068 May 1996 EP
0800800 Oct 1997 EP
0847733 Jun 1998 EP
0870483 Oct 1998 EP
1029517 Aug 2000 EP
1034751 Sep 2000 EP
1157673 Nov 2001 EP
1190685 Mar 2002 EP
1212991 Jun 2002 EP
1245203 Oct 2002 EP
1255507 Nov 2002 EP
1356789 Oct 2003 EP
1433438 Jun 2004 EP
1488763 Dec 2004 EP
1767240 Mar 2007 EP
2134301 Dec 2009 EP
2626046 Jul 1989 FR
453944 Sep 1936 GB
07315147 Dec 1995 JP
2004-506477 Mar 2004 JP
2007-504891 Mar 2007 JP
4827965 Nov 2011 JP
4933018 May 2012 JP
9417754 Aug 1994 WO
9503010 Feb 1995 WO
9626689 Sep 1996 WO
9733534 Sep 1997 WO
9820810 May 1998 WO
9915108 Apr 1999 WO
9938457 Aug 1999 WO
9949928 Oct 1999 WO
9955253 Nov 1999 WO
0045742 Aug 2000 WO
0049971 Aug 2000 WO
0064375 Nov 2000 WO
0132102 May 2001 WO
0158384 Aug 2001 WO
0176508 Oct 2001 WO
0101889 Nov 2001 WO
0215820 Feb 2002 WO
0249544 Jun 2002 WO
03055414 Jul 2003 WO
03075797 Sep 2003 WO
03101343 Dec 2003 WO
2004019820 Mar 2004 WO
2004028408 Apr 2004 WO
2004032802 Apr 2004 WO
2004058384 Jul 2004 WO
2005067816 Jul 2005 WO
2005072652 Aug 2005 WO
2005104991 Nov 2005 WO
2005032403 Dec 2005 WO
2006010636 Feb 2006 WO
2006010638 Feb 2006 WO
2006014768 Feb 2006 WO
2006025847 Mar 2006 WO
2006036912 Apr 2006 WO
2006047977 May 2006 WO
2006064153 Jun 2006 WO
2007073413 Jun 2007 WO
2006026778 Nov 2007 WO
2007131798 Nov 2007 WO
2007135090 Nov 2007 WO
2008006830 Jan 2008 WO
2008022949 Feb 2008 WO
2008022950 Feb 2008 WO
2008025762 Mar 2008 WO
2008028964 Mar 2008 WO
2008055980 May 2008 WO
2008068279 Jun 2008 WO
2008101987 Aug 2008 WO
2008119837 Oct 2008 WO
2009030748 Mar 2009 WO
Non-Patent Literature Citations (121)
Entry
U.S. Appl. No. 10/362,040, filed Jun. 27, 2003 Office Action dated Aug. 2, 2006.
U.S. Appl. No. 10/362,040, filed Jun. 27, 2003 Office Action dated Dec. 10, 2007.
U.S. Appl. No. 10/362,040, filed Jun. 27, 2003 Office Action dated Feb. 23, 2010.
U.S. Appl. No. 10/362,040, filed Jun. 27, 2003 Office Action dated Jan. 10, 2006.
U.S. Appl. No. 10/362,040, filed Jun. 27, 2003 Office Action dated Jul. 15, 2009.
U.S. Appl. No. 10/362,040, filed Jun. 27, 2003 Office Action dated Jun. 23, 2005.
U.S. Appl. No. 10/362,040, filed Jun. 27, 2003 Office Action dated Jun. 5, 2007.
U.S. Appl. No. 12/300,985, filed Aug. 6, 2010 Final Office Action dated Aug. 15, 2012.
U.S. Appl. No. 12/300,985, filed Aug. 6, 2010 Non-Final Office Action dated Mar. 15, 2012.
U.S. Appl. No. 12/300,985, filed Aug. 6, 2010 Notice of Allowance dated Nov. 16, 2012.
U.S. Appl. No. 12/301,019, filed Feb. 2, 2009 Advisory Action dated Apr. 27, 2011.
U.S. Appl. No. 12/301,019, filed Feb. 2, 2009 Final Office Action dated Feb. 7, 2011.
U.S. Appl. No. 12/301,019, filed Feb. 2, 2009 Non-Final Office Action dated Sep. 3, 2010.
U.S. Appl. No. 12/373,116, filed Jul. 14, 2009 Advisory Action dated Jul. 26, 2011.
U.S. Appl. No. 12/373,116, filed Jul. 14, 2009 Examiner's Answer dated Jan. 3, 2013.
U.S. Appl. No. 12/373,116, filed Jul. 14, 2009 Final Office Action dated Apr. 27, 2011.
U.S. Appl. No. 12/373,116, filed Jul. 14, 2009 Final Office Action dated Mar. 29, 2012.
U.S. Appl. No. 12/373,116, filed Jul. 14, 2009 Non-Final Office Action dated Nov. 10, 2010.
U.S. Appl. No. 12/373,116, filed Jul. 14, 2009 Non-Final Office Action dated Nov. 18, 2011.
U.S. Appl. No. 12/373,116, filed Jul. 14, 2009 Notice of Panel Decision dated Aug. 20, 2012.
U.S. Appl. No. 12/438,102, filed Feb. 19, 2009 Non-Final Office Action dated Nov. 15, 2010.
U.S. Appl. No. 12/438,330, filed Feb. 20, 2009 Advisory Action dated Oct. 14, 2010.
U.S. Appl. No. 12/438,330, filed Feb. 20, 2009 Advisory Action dated Oct. 20, 2011.
U.S. Appl. No. 12/438,330, filed Feb. 20, 2009 Final Office Action dated Aug. 11, 2011.
U.S. Appl. No. 12/438,330, filed Feb. 20, 2009 Non-Final Office Action dated Jun. 7, 2012.
U.S. Appl. No. 12/438,330, filed Feb. 20, 2009 Notice of Allowance dated Sep. 25, 2012.
U.S. Appl. No. 12/438,330, filed Feb. 20, 2009 Office Action dated Aug. 5, 2010.
U.S. Appl. No. 12/438,330, filed Feb. 20, 2009 Office Action dated Mar. 16, 2010.
U.S. Appl. No. 12/438,330, filed Feb. 20, 2009 Office Action dated Mar. 4, 2011.
U.S. Appl. No. 12/438,527, filed Feb. 23, 2009 Advisory Action dated May 24, 2012.
U.S. Appl. No. 12/438,527, filed Feb. 23, 2009 Final Office Action dated Mar. 7, 2012.
U.S. Appl. No. 12/438,527, filed Feb. 23, 2009 Non-Final Office Action dated Jul. 11, 2011.
U.S. Appl. No. 12/440,415, filed Mar. 6, 2009 Final Office Action dated Jan. 10, 2013.
U.S. Appl. No. 12/440,415, filed Mar. 6, 2009 Non-Final Office Action dated Jul. 2, 2012.
U.S. Appl. No. 12/514,177, filed May 8, 2009 Advisory Action dated Sep. 10, 2012.
U.S. Appl. No. 12/514,177, filed May 8, 2009 Final Office Action dated Apr. 27, 2011.
U.S. Appl. No. 12/514,177, filed May 8, 2009 Final Office Action dated Jul. 11, 2012.
U.S. Appl. No. 12/514,177, filed May 8, 2009 Non-Final Office Action dated Jan. 5, 2011.
U.S. Appl. No. 12/514,177, filed May 8, 2009 Non-Final Office Action dated Mar. 13, 2012.
U.S. Appl. No. 12/517,096, filed Jun. 1, 2009 Final Office Action dated Oct. 31, 2011.
U.S. Appl. No. 12/517,096, filed Jun. 1, 2009 Non-Final Office Action dated Jun. 18, 2012.
U.S. Appl. No. 12/517,096, filed Jun. 1, 2009 Non-Final Office Action dated May 6, 2011.
U.S. Appl. No. 12/517,096, filed Jun. 1, 2009 Non-Final Office Action dated Nov. 28, 2012.
U.S. Appl. No. 12/517,096, filed Jun. 1, 2009 Notice of Panel Decision dated Mar. 23, 2012.
U.S. Appl. No. 12/528,289, filed Aug. 26, 2009 Non-Final Office Action dated Jan. 27, 2012.
U.S. Appl. No. 12/594,531, filed Oct. 2, 2009 Advisory Action dated Jan. 10, 2012.
U.S. Appl. No. 12/594,531, filed Oct. 2, 2009 Final Office Action dated Nov. 4, 2011.
U.S. Appl. No. 12/594,531, filed Oct. 2, 2009 Non-Final Office Action dated Dec. 17, 2010.
U.S. Appl. No. 12/594,531, filed Oct. 2, 2009 Non-Final Office Action dated May 12, 2011.
U.S. Appl. No. 12/594,531, filed Oct. 2, 2009 Non-Final Office Action dated Oct. 2, 2012.
Database Wikipedia, Sep. 11, 2007, “Lumen (anatomy)” XP 002453737 abstract.
EP 07787316.4 filed Jul. 10, 2007 Examination Report dated Dec. 23, 2011.
EP 07802603.6 filed Aug. 14, 2007 Office Action dated Dec. 13, 2010.
EP 07820066.4 filed Mar. 31, 2009 Examination Report dated Dec. 27, 2011.
EP 09177588 filed Aug. 14, 2007 Search Report dated Aug. 12, 2011.
EP 12174308.2 filed Apr. 3, 2008 European Search Report dated Sep. 10, 2012.
JP 2010-523512 filed Sep. 5, 2008 Office Action dated Sep. 25, 2012.
PCT/EP2001/009467 International Preliminary Examination Report Sep. 17, 2002.
PCT/EP2001/009467 International Search Report dated Feb. 18, 2002.
PCT/EP2007/004407 filed May 16, 2007 International Preliminary Report on Patentability dated Sep. 29, 2008.
PCT/EP2007/004407 filed May 16, 2007 Search Report dated Sep. 26, 2007.
PCT/EP2007/004407 filed May 16, 2007 Written Opinion dated Sep. 26, 2007.
PCT/EP2007/054822 filed on May 18, 2007 International Preliminary Report on Patentability dated Nov. 18, 2008.
PCT/EP2007/054822 filed on May 18, 2007 Search Report dated Sep. 18, 2007.
PCT/EP2007/054822 filed on May 18, 2007 Written Opinion dated Nov. 18, 2008.
PCT/EP2007/057041 filed Jul. 10, 2007 International Preliminary Report on Patentability dated Jan. 13, 2009.
PCT/EP2007/057041 filed Jul. 10, 2007 International Search Report dated Oct. 18, 2007.
PCT/EP2007/057041 filed Jul. 10, 2007 Written Opinion Jan. 10, 2009.
PCT/EP2007/058415 filed on Aug. 14, 2007 International Preliminary Report on Patentability dated Feb. 24, 2009.
PCT/EP2007/058415 filed on Aug. 14, 2007 Search Report dated Nov. 30, 2007.
PCT/EP2007/058415 filed on Aug. 14, 2007 Written Opinion dated Nov. 30, 2007.
PCT/EP2007/058416 filed Aug. 14, 2007 International Preliminary Report on Patentability dated Feb. 24, 2009.
PCT/EP2007/058416 filed Aug. 14, 2007 International Search Report dated Nov. 22, 2007.
PCT/EP2007/058416 filed Aug. 14, 2007 Written Opinion dated Feb. 23, 2009.
PCT/EP2007/058912 filed on Aug. 28, 2007 International Preliminary Report on Patentability dated Nov. 5, 2008.
PCT/EP2007/058912 filed on Aug. 28, 2007 Search Report dated Nov. 12, 2007.
PCT/EP2007/058912 filed on Aug. 28, 2007 Written Opinion dated Nov. 12, 2007.
PCT/EP2007/059407 filed Sep. 7, 2007 International Preliminary Report on Patentability and Written Opinion dated Mar. 10, 2009.
PCT/EP2007/059407 filed Sep. 7, 2007 International Search Report dated Jul. 3, 2008.
PCT/EP2007/059407 filed Sep. 7, 2007 Written Opinion dated Mar. 10, 2009.
PCT/EP2007/062155 filed on Nov. 9, 2007 Search Report dated Mar. 12. 2008.
PCT/EP2007/062155 filed on Nov. 9, 2007 Written Opinion dated Mar. 12, 2009.
PCT/EP2007/062155 filed on Novermber 9, 2007 International Preliminary Report on Patentability dated Oct. 15, 2008.
PCT/EP2007/063347 filed Dec. 5, 2007 Search Report dated Jun. 10, 2009.
PCT/EP2007/063347 filed Dec. 5, 2007 Written Opinion mailed Jun. 10, 2009.
PCT/EP2007/063347 filed on Dec. 5, 2007 Search Report mailed Feb. 4, 2008.
PCT/EP2008/052121 filed Feb. 21, 2008 International Preliminary Report on Patentability dated Aug. 26, 2009.
PCT/EP2008/052121 filed Feb. 21, 2008 International Search Report dated May 19, 2008.
PCT/EP2008/052121 filed Feb. 21, 2008 Written Opinion dated May 9, 2008.
PCT/EP2008/054007 filed Apr. 3, 2008 International Preliminary Report on Patentability dated Jul. 27, 2009.
PCT/EP2008/054007 filed Apr. 3, 2008 Search Report dated Jan. 30, 2009.
PCT/EP2008/054007 filed Apr. 3, 2008 Written Opinion dated Jan. 30, 2009.
PCT/EP2008/061775 filed Sep. 5, 2008 International Search Report dated Apr. 22, 2009.
PCT/EP2008/061775 filed Sep. 5, 2008 Written Opinion dated Apr. 22, 2009.
U.S. Appl. No. 10/362,040, filed Jun. 27, 2003 Advisory Action dated Dec. 16, 2010.
U.S. Appl. No. 10/362,040, filed Jun. 27, 2003 Advisory Action dated Jan. 9, 2009.
U.S. Appl. No. 10/362,040, filed Jun. 27, 2003 Advisory Action dated Nov. 29, 2006.
U.S. Appl. No. 10/362,040, filed Jun. 27, 2003 Final Office Action dated Aug. 30, 2010.
U.S. Appl. No. 10/362,040, filed Jun. 27, 2003 Notice of Allowance dated Jun. 22, 2011.
U.S. Appl. No. 10/362,040, filed Jun. 27, 2003 Office Action dated Aug. 18, 2008.
U.S. Appl. No. 13/279,189, filed Oct. 21, 2011 Non-Final Office Action dated Oct. 17, 2012.
PCT/EP2007/054822 filed May 16, 2007 International Preliminary Report on Patentability dated Nov. 18, 2008.
U.S. Appl. No. 12/301,019, filed Feb. 2, 2009 Notice of Allowance dated Jul. 9, 2013.
U.S. Appl. No. 12/438,102, filed Feb. 19, 2009 Final Office Action dated Apr. 21, 2011.
U.S. Appl. No. 12/438,102, filed Feb. 19, 2009 Advisory Action dated Jul. 12, 2011.
U.S. Appl. No. 12/438,102, filed Feb. 19, 2009 Notice of Allowance dated Dec. 6, 2011.
U.S. Appl. No. 12/438,527, filed Feb. 23, 2009 Non-Final Office Action dated Oct. 9, 2014.
U.S. Appl. No. 12/438,527, filed Feb. 23, 2009 Final Office Action dated May 14, 2015.
U.S. Appl. No. 12/440,415, filed Mar. 6, 2009 Notice of Allowance dated Apr. 3, 2013.
U.S. Appl. No. 12/514,177, filed May 8, 2009 Notice of Allowance dated Jun. 13, 2013.
U.S. Appl. No. 12/517,096, filed Jun. 1, 2009 Notice of Allowance dated Mar. 18, 2013.
U.S. Appl. No. 12/528,289, filed Aug. 26, 2009 Notice of Allowance dated Jun. 29, 2012.
U.S. Appl. No. 12/594,531, filed Oct. 2, 2009 Notice of Allowance dated May 7, 2013.
U.S. Appl. No. 13/279,189, filed Oct. 21, 2011 Final Office Action dated May 2, 2013.
U.S. Appl. No. 13/279,189, filed Oct. 21, 2011 Notice of Allowance dated May 6, 2014.
U.S. Appl. No. 13/402,787, filed Feb. 22, 2012 Notice of Allowance dated Apr. 9, 2013.
U.S. Appl. No. 14/045,603, filed Oct. 3, 2013 Non-Final Office Action dated Dec. 15, 2014.
U.S. Appl. No. 14/045,603, filed Oct. 3, 2013 Notice of Allowance dated Mar. 30, 2015.
U.S. Appl. No. 13/975,147, filed Aug. 23, 2013 Non-Final Office Action dated May 15, 2014.
U.S. Appl. No. 13/975,147, filed Aug. 23, 2013 Notice of Allowance dated Feb. 11, 2015.
U.S. Appl. No. 12/676,584, filed Mar. 4, 2010 Non-Final Office Action dated May 24, 2013.
Related Publications (1)
Number Date Country
20130218260 A1 Aug 2013 US
Continuations (1)
Number Date Country
Parent 12300985 US
Child 13849312 US